Catalog No.
Product Name
Application
Product Information
Citations
-
CB2 inverse agonist
SR 144528 is a selective peripheral cannabinoid receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.- Ming Tang, .et al. , Cell Death Dis, 2018, Jun; 9(6): 601 PMID: 29789558
-
GnRH antagonist
Degarelix acetate is a gonadotropin releasing hormone (GnRH) receptor antagonist. - Ganirelix is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist)
-
GnRH antagonist
Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. -
GnRH agonist
Leuprolide acetate is a GnRH analog; leuprolide acetate acts as an agonist at pituitary GnRH receptors. -
GnRH agonist
Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. -
GnRH agonist
Triptorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. -
GnRH/LHRH receptor agonist
Leuprorelin is a Gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, LHRH) receptor agonist. Suppresses estradiol, LH and FSH serum levels and represses the growth of experimental rat endometriosis. -
GnRH agonist
Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which acts as an analog of GnRH. -
gonadotropin-releasing hormone agonist
Buserelin Acetate is a gonadotropin-releasing hormone agonist (GnRH agonist). -
GnRH antagonist
Cetrorelix acetate is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity used in infertility treatment. The IC50 of 1.21 nM. -
GnRHR antagonist
Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). -
GnRH peptide agonist
Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor. It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells. -
GnRH receptor antagonist
Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. -
GnRH Receptor agonist
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis. -
GnRH Antagonist
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist that effectively inhibits the endogenous luteinizing hormone surge during ovarian stimulation. This compound is utilized in research to study its role in reproductive processes, particularly in the modulation of ovarian function. Additionally, Cetrorelix has demonstrated the ability to reduce cyclophosphamide-induced ovarian follicular destruction in animal models, making it invaluable for studies related to ovarian preservation and fertility. -
LHRH Analogue
[D-Lys6]-LH-RH is a potent analogue of Luteinizing-hormone-releasing hormone (LHRH) that acts as a GnRH receptor agonist. This compound demonstrates significant activity in promoting the release of luteinizing hormone, making it valuable for endocrine research. Its applications extend to studies focused on reproductive biology, fertility treatments, and hormone regulation. -
GnRHR Antagonist
Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. This compound effectively inhibits the GnRH signaling pathway, making it a valuable tool in prostate cancer research. It is used to study the modulation of hormone levels and the impact on tumor growth dynamics. -
GnRH Antagonist
Teverelix is a GnRH antagonist that binds competitively and reversibly to GnRH receptors, inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This compound plays a critical role in the study of disorders related to reproductive hormone regulation, including prostatic hyperplasia, endometriosis, and prostate cancer. Its selective mechanism makes it a valuable tool for research in endocrinology and oncology. -
GnRH Receptor Antagonist
SKI2496 is a potent GnRH receptor antagonist that exhibits an IC50 of 0.25 nM for human GnRHR, demonstrating high specificity across species with values of 13.2 nM for monkey and 279.2 nM for rat receptors. This compound effectively inhibits Ca2+ influx with an IC50 of 0.76 nM and blocks ERK1/2 phosphorylation with an IC50 of 2.6 nM. SKI2496 is utilized in research focused on sex hormone-dependent disorders, particularly for its ability to reduce serum LH concentrations. -
LH-R Antagonist
BAY-899 is a selective luteinizing hormone receptor (LH-R) antagonist, exhibiting IC50 values of 185 nM for human LH and 46 nM for rat LH. This compound effectively reduces sex hormone levels, making it a valuable tool for research in hormonal regulation and reproductive health. BAY-899 can be utilized to study the physiological and pathological roles of LH signaling in various biological contexts. -
FSH Antagonist
FSH receptor-binding inhibitor fragment (bi-10) is a specific antagonist of the follicle-stimulating hormone (FSH) receptor (FSHR). This compound effectively inhibits FSH from binding to its receptor, thereby modifying FSH activity at the receptor level. Research indicates that bi-10 can suppress ovulation and induce follicular atresia in murine models. Additionally, it may offer potential therapeutic strategies for mitigating ovarian cancer by downregulating the overexpression of FSHR and estrogen receptor beta (ERβ) in ovarian tissues. -
GnRH-R Antagonist
GnRH-R antagonist-3 is a potent gonadotropin-releasing hormone receptor (GnRH-R) antagonist with IC50 values of 94 nM for rat GnRH-R and 275 nM for human GnRH-R. This compound demonstrates significant potential in the study of hormone-dependent diseases, including endometriosis, breast cancer, and prostate cancer. It serves as a valuable tool for researchers investigating the therapeutic mechanisms and biological pathways associated with these conditions. -
LHRH Antagonist
Ramorelix is an LHRH antagonist that inhibits the action of luteinizing hormone, thereby interfering with hormone-driven tumor progression. This compound is primarily utilized in cancer research focused on hormone-sensitive tumors, offering insights into therapeutic strategies targeting the endocrine system. Ramorelix's biological activity makes it a valuable tool for exploring mechanisms of tumor inhibition and advancing anti-cancer therapies. -
LH-R Antagonist
BAY-298 is a selective luteinizing hormone receptor (LH-R) antagonist with an IC50 of 96 nM for human LH, 23 nM for rat LH, and 78 nM for cynomolgus monkey LH. This orally active compound effectively reduces sex hormone levels, making it a valuable tool for research focused on reproductive biology and endocrine regulation. Its specificity and potency position BAY-298 as a critical reagent for studies investigating LH-R signaling pathways and potential therapeutic applications in hormone-related disorders. -
GnRH Analogue
Lecirelin is a synthetic gonadotropin-releasing hormone (GnRH) analogue that functions as a GnRH agonist. It plays a crucial role in the regulation of reproductive hormones and is primarily utilized in the study of bovine ovarian follicular cysts. This compound is essential for investigating reproductive physiology and addressing disorders related to ovarian function in cattle. -
GnRHR Agonist
DCOIT is a potent agonist of the gonadotropin-releasing hormone receptor (GnRHR), promoting the synthesis of follicle-stimulating hormone and luteinizing hormone in the brain. This isothiazolinone compound engages G protein-coupled receptors, influencing MAPK and calcium signaling pathways. Its capacity to modulate hormone production makes DCOIT valuable for studies related to reproductive biology and endocrinology. -
GnRH Agonist
(Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH is a potent agonist of gonadotropin-releasing hormone (GnRH). This compound exhibits significant biological activity in the modulation of hormone secretion and can be utilized as an internal standard for LC-MS analysis of leuprorelin acetate. (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH is relevant in biochemical research and has potential applications in the study of fertility and reproductive health. -
Luteinizing Hormone-releasing Hormone
Luteinizing Hormone Releasing Hormone (LH-RH), salmon is a decapeptide that primarily targets the hypothalamus to regulate the release of luteinizing hormone. This peptide plays a critical role in controlling reproductive functions, influencing both male and female gonadal activity. LH-RH is widely used in research applications related to endocrinology, reproductive biology, and hormone regulation. -
LH-R Agonist
Org 43553 is a selective luteinizing hormone receptor (LH-R) agonist characterized by its oral bioactivity and low molecular weight. It exhibits potent agonistic effects on human LH and follicle-stimulating hormone (FSH) receptors, with EC50 values of 3.7 nM and 110 nM, respectively. This compound is valuable for research focusing on endocrine signaling and receptor-mediated pathways. -
LHRH Antagonist
Antide (D-21074) is a potent LHRH antagonist that specifically inhibits luteinizing hormone-releasing hormone receptors. It displays significant biological activity in blocking the secretion of gonadotropins, making it instrumental in research related to hormone-dependent cancers, particularly prostatic cancer. This compound serves as a valuable tool for studying the effects of LHRH modulation in various therapeutic applications. -
GnRH-R Antagonist
BAY-784 is a gonadotropin-releasing hormone receptor (GnRH-R) antagonist that demonstrates inhibitory activity with IC50 values of 21 nM for human and 24 nM for rat GnRH-R. This compound is utilized in research to investigate the role of GnRH-R in reproductive biology and endocrine signaling. Its effectiveness makes it a valuable tool for studying hormonal regulation and potential therapeutic applications in reproductive disorders. -
GnRH Antagonist
Ganirelix is a competitive and selective gonadotropin-releasing hormone (GnRH) antagonist. It effectively inhibits the action of endogenous GnRH, thereby preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This compound is primarily utilized in reproductive research and in the management of controlled ovarian stimulation protocols in assisted reproductive technology. -
GnRH Antagonist
Linzagolix is a potent non-peptide gonadotropin-releasing hormone (GnRH) antagonist that is orally active. It has demonstrated significant biological activity in the modulation of hormone secretion and is utilized in research focused on uterine fibroids, endometriosis, and adenomyosis. This compound provides a valuable tool for investigating reproductive health and therapeutic interventions in related disorders. -
BAY-899 R-enantiomer
(R)-BAY-899 is the R-enantiomer of the selective luteinizing hormone receptor (LH-R) antagonist BAY-899. This compound exhibits IC50 values of 185 nM for human LH and 46 nM for rat LH, indicating its potency in blocking LH signaling pathways. It is primarily used in research applications focusing on reproductive biology and investigating the effects of LH antagonism in various physiological processes. -
GnRH Receptor Antagonist
Lumigolix is a GnRH receptor antagonist that effectively inhibits gonadotropin-releasing hormone signaling. This compound demonstrates potential in the treatment and research of endometriosis by modulating hormone levels and preventing the effects of GnRH on pituitary hormone release. Its role in lowering estrogen production makes it a valuable reagent for studying reproductive health and related disorders. -
Reproductive Regulator
[Gln8]-C517 (LH-RH), chicken is an avian hypothalamic peptide that acts as a reproductive regulator by stimulating the release of gonadotropins from the anterior pituitary gland. This compound plays a crucial role in regulating reproductive functions in avian species. It is valuable for research applications focused on reproductive endocrinology and the hormonal regulation of fertility in poultry and other avian models. -
recLH and Org 43553 Inhibitor
LUF5771 is an allosteric inhibitor targeting recombinant luteinizing hormone (recLH) and Org 43553. This compound exhibits the ability to partially activate the LH receptor with low efficacy, making it relevant for studies on LH receptor modulation. Its unique pharmacological profile positions LUF5771 as a valuable tool in research exploring reproductive physiology and endocrine signaling pathways. -
hGnRH-R Antagonist
BAY 1214784 is a potent and selective antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R), classified as a spiroindoline derivative. This compound effectively reduces plasma luteinizing hormone levels by up to 49%, demonstrating low pharmacokinetic variability and good tolerability in biological assays. BAY 1214784 holds promise for research applications related to uterine fibroids, providing a valuable tool for studies in reproductive health and hormone regulation. -
GnRH Agonist
LGnRH-III, derived from the sea lamprey, acts as a weak agonist of gonadotropin-releasing hormone (GnRH). This compound has been explored for its potential antitumor activities, making it a valuable tool in cancer research. Its mechanism involves the modulation of hormonal pathways, which may provide insights into therapeutic strategies targeting GnRH receptors in various malignancies.
